Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism involves a transient DNA double strand break repair deficit induced by lapatinib and subsequent activation of the intrinsic pathway of apoptosis. Further dissection of the mechanism reveals that EGFR and BRCA1 can be found in the same protein complex, which is reduced by lapatinib. Interestingly, lapatinib also increases cytosolic BRCA1 and EGFR, away from their nuclear DNA repair substrates. Taken together, these results reveal a novel regulation of homologous recombination repair involving EGFR and BRCA1 interaction and alteration of subcellular localization. Additionally, a contextual synthetic lethality may exist between combined EGFR and PARP inhibitors.
References
[1]
Chacon RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12 Suppl 2: S3.
[2]
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. New England Journal of Medicine 361: 123–134.
[3]
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet 376: 235–244.
[4]
O'Shaughnessy J, Schwartzberg L, Danso M, Rugo H, Miller K, et al. (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29.
[5]
Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, et al. (2012) Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer
[6]
Martin V, Botta F, Zanellato E, Molinari F, Crippa S, et al. (2012) Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 27: 785–792.
[7]
Liu D, He J, Yuan Z, Wang S, Peng R, et al. (2011) EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol
[8]
Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, et al. (2011) IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 130: 465–475.
[9]
Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E, Martin-Castillo B, Del Barco S, et al. (2008) Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol 33: 1165–1176.
[10]
Nowsheen S, Bonner JA, Yang ES (2011) The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 99: 331–338.
[11]
Nowsheen S, Bonner JA, LoBuglio AF, Trummell H, Whitley AC, et al. (2011) Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer. PLoS ONE 6: e24148.
[12]
Li L, Wang H, Yang ES, Arteaga CL, Xia F (2008) Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 68: 9141–9146.
[13]
Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, et al. (2004) Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24: 708–718.
[14]
Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, et al. (2011) p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 71: 5546–5557.
[15]
Wang H, Yang ES, Jiang J, Nowsheen S, Xia F (2010) DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res 70: 6258–6267.
[16]
Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7: 98–107.
[17]
Subik K, Lee JF, Baxter L, Strzepek T, Costello D, et al. (2010) The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 4: 35–41.
[18]
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515–527.
[19]
Vranic S, Gatalica Z, Wang ZY (2011) Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncology letters 2: 1131.
[20]
Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798–4811.
[21]
Javle M, Curtin NJ (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105: 1114–1122.
[22]
Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) [gamma]H2AX and cancer. Nat Rev Cancer 8: 957–967.
Yang ES, Xia F (2010) BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS J 277: 3079–3085.
[25]
Laulier C, Barascu A, Guirouilh-Barbat J, Pennarun G, Le Chalony C, et al. (2011) Bcl-2 Inhibits Nuclear Homologous Recombination by Localizing BRCA1 to the Endomembranes. Cancer Res 71: 3590–3602.
[26]
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology 8: 1197–1206.
[27]
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.
[28]
Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170–4176.
[29]
Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166–2174.
[30]
Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. International Journal of Radiation Biology 83: 781–791.
[31]
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350–7356.
[32]
Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683–692.
[33]
Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012: 217185.
[34]
Anido J, Matar P, Albanell J, Guzman M, Rojo F, et al. (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274–1283.
[35]
Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76: 157–161.
[36]
Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, et al. (2011) In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol 101: 147–151.
[37]
Lehmann Bd Fau - Bauer JA, Bauer Ja Fau - Chen X, Chen X Fau - Sanders ME, Sanders Me Fau - Chakravarthy AB, Chakravarthy Ab Fau - Shyr Y, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
